On October 12, Singapore's Health Sciences Authority (HSA) announced a series of initiatives aimed at strengthening the country’s position as a healthcare innovation and regulatory hub. The set of measures includes a (i) new international regulatory partnerships, (ii) streamlined clinical trial processes, and (iii) accelerated pathways for innovative therapies to reach patients.
To support earlier-stage innovation, HSA announced a new Regulatory Innovation Corridor with the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), allowing developers of breakthrough therapies, including those using artificial intelligence, to engage both regulators through a coordinated process. HSA also announced that a common entry point for clinical research and regulatory engagement will be launched in early 2027 by Enterprise Singapore, the Economic Development Board, HSA, and the Singapore Clinical Research Institute. In addition, approval timelines for selected lower-risk Phase 3 clinical trials could be reduced from 30 days to 15 days, further supporting Singapore’s efforts to attract clinical research activities.
To accelerate patient access to innovative therapies, HSA and the Agency for Care Effectiveness (ACE) will introduce an ACE-HSA Priority Track beginning in November 2026. The initiative will allow selected innovative products, including therapeutic drugs and cell, tissue, and gene therapy products, to undergo regulatory review and health technology assessment concurrently rather than sequentially. According to ACE, this could reduce the time between regulatory approval and the first health technology assessment decision from more than one year to approximately six to nine months. Priority will be given to products addressing unmet clinical needs, supporting Singapore’s healthcare priorities, and demonstrating plans for commercialization in Singapore. Separately, HSA announced plans to establish a Healthcare Industry Advisory Council in the first half of 2027 to provide industry input on regulatory planning, emerging risks, and future capability needs.
On October 22 US-ASEAN Business Council hosted a discussion with Adjunct Professor (Dr.) Raymond Chua, CEO of Health Sciences Authority to discuss regulatory innovation, emerging health technologies, early regulatory engagement, and enhancing regulatory alignment across ASEAN. A key follow-up from the meeting is a proposed private sector dialogue with ASEAN healthcare regulatory agencies in 2027.
